Twenty-five plus years of experience in pharmaceutical industry with increasing supervisory and strategic responsibilities. Significant background in most aspects of the drug discovery process in neurologic diseases. Externally recognized expertise ranging from target identification and validation through nonclinical and early phase clinical development. Committed drug hunter with successful track record of delivering multiple high quality clinical candidates. Retired from Eli Lilly in 2014 and now providing independent neuroscience pharmaceutical consulting. Current SAB member and drug discovery consultant for the Tau Consortium.